Synthesis and antimicrobial activity of cyclopentyl-substituted halogenophenoxyacetic acids and their amides

A series of cyclopentylhalogenoanisoles have been synthesized by alkylation of o- and p-chloro- and fluoroanisoles with cyclopentene in the presence of BF₃·H₃PO₄. The compositions and structures of the products were studied by GC, IR, and NMR spectroscopy. Demethylation of the cyclopentylhalogenoanisoles yielded cyclopentylhalogenophenols, which were reacted with chloroacetic acid and chloroacetamide to obtain cyclopentyl-substituted chloro- and fluorophenoxyacetic acids and their amides. Results of studying the antimicrobial activity of the synthesized acids and their amides against S. viridans, S. flexneri, P.aeruginosa, B. antracoides, K. rhinoscleromatis, and C. albicans are presented. All substances show moderate activity against the test microbes (minimum bacteriostatic concentrations from 31.25 to 125 μg/mL). Introduction of a cyclopentyl substituent into the structure of 2-chlorophenoxyacetic acid improves the activity against S. viridans, P. aeruginosa, and K. rhinoscleromatis. These data can be used to study the relationship between the structures and antimicrobial activity.     

Synthesis and the Antiinflammatory Activity of New N-Acyl-5-Bromanthranilamides

Nineteen N-acyl-5-bromanthranilic acid amides were synthesized via acylation of 5-bromanthranilamide with suitable anhydrides. The antimicrobial activity of the synthesized compounds with respect to Staphylococcus aureus and Escherichia coli was evaluated. Compounds with diphenyl, furoyl, and tetrachlorophthalyl moieties in the acyl part of the molecule showed significant inhibition of microbial growth. The minimum inhibiting concentrations of this compounds were 15.6 μg/ml against S. aureus and 15.6 – 31 μg/ml against E. coli. Other tested amides were considerably less active.__________Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 39, No. 1, pp. 17 – 18, January, 2005.     

Synthesis, anticancer and antibacterial activities of piperine analogs

A series of piperine analogs were synthesized by the condensation of piperic acid with different aminoacids and substituted aniline. The synthesized compounds (4a–4e) were evaluated for their anticancer activity against human cancer cell lines (MCF-7, Breast Cancer cell line, and Hela cervix cell line) and antibacterial activity against human pathogens (Escherichia coli, Klebsiella pneumoniae, Salmonella typhi, Shigella dysenteriae, Bacillus subtilis, Staphylococcus aureus, Pseudomonas aeruginosa). The efficacies of the synthesized compounds were superior to those of piperine in all tested human cancer cell lines. Among the tested conjugates, 4c showed significant anticancer activity against Hela cervix cell line with IC₅₀ of 0.736 μmol and 4a showed significant activity against breast cancer cell line. The antibacterial activity of the tested compounds was also found to be superior to that of piperine. The approach is novel as the abundantly available natural product piperine is utilized as precursor for the synthesis of new potential antimicrobial and anticancer agents.     

Design,Synthesis, and Pharmacological Investigation of Iodined Salicylimines,New Prototypes of Antimicrobial Drug Candidates

A series of 3,5‐diiodo‐salicylalidene Schiff bases (compounds 1–35 ) has been synthesized and tested for antimicrobial activity. The compounds were assayed for antibacterial activities by the MTT method. Some of the compounds inhibit the growth of a broad range of bacteria including the species of Bacillus subtilis, Staphylococcus aureus, Streptococcus faecalis, Pseudomonas aeruginosa, Escherichia coli, and Enterobacter cloacae. Among them, compounds 2‐[(4‐chloro‐phenylimino)methyl]‐4,6‐diiodo‐phenol 11 and 2,4‐diiodo‐6‐[(2‐morpholin‐4‐yl‐ethylimino)methyl]phenol 19 showed the most potent antibacterial activity with MIC of 3.1, 12.9, 3.3, 6.5, 12.9, 3.3 and 3.2, 12.8, 3.2, 12.8, 12.8, 3.2 μM against B. subtilis, S. aureus, S. faecalis, P. aeruginosa, E. Coli, and E. cloacae, respectively.     

Synthesis and Biological Evaluation of Novel Pyrazoles and Pyrazolo[3,4‐d]pyrimidines Incorporating a Benzenesulfonamide Moiety

Synthesis and biological evaluation of novel pyrazoles and pyrazolo[3,4‐d]pyrimidines are reported. Fourteen compounds were selected by the NCI and tested for their preliminary in‐vitro anticancer activity, whereas all the synthesized compounds were evaluated for their in‐vitro antimicrobial activity. Compound 12a was proven to possess the highest anticancer activity with a broad spectrum profile. It showed particular effectiveness towards leukemia HL‐60 (TB), K‐562, non‐small cell lung cancer NCI‐H23, and colon cancer HT 29, KM 12 cell lines (GI₅₀ = 6.59, 4.44, 1.37, 3.33, and 9.63 μM, respectively). Out of the synthesized compounds, thirteen derivatives were found to display pronounced antimicrobial activity especially against P. aeruginosa. Compounds 2c , 5b , 10 , 11b , 17b , 18b , and 19 were proven to be the most active with a broad spectrum of activity. Compound 19 was found to be equipotent to ampicillin against B. subtilis, whereas compounds 11b and 19 were four times superior to ampicillin against P. aeruginosa, while compounds 5b and 18b were equipotent to ampicillin against the same organism. Moreover, compounds 2c , 10 , and 11b were nearly equipotent to ampicillin against E. coli. On the other hand, compounds 2c , 5b , 10 , 11a , 17b , and 18b exerted nearly half the activity of clotrimazole against C. albicans.     

Synthesis,antibacterial evaluation,and DNA gyrase inhibition profile of some new quinoline hybrids

Antibiotic‐resistant bacteria continue to play an important role in human health and disease. Inventive strategies are necessary to develop new therapeutic leads to challenge drug‐resistance problems. From this perception, new quinoline hybrids bearing bioactive pharmacophores were synthesized. The newly synthesized compounds were evaluated for their in vitro antibacterial activity against nine bacterial pathogenic strains. The results revealed that most compounds exhibited good antibacterial activities. Seven compounds ( 2b , 3b , 4 , 6 , 8b , and 9c,d ) displayed enhanced activity against methicillin‐resistant Staphylococcus aureus compared to ampicillin. These compounds were subjected to an in vitro S. aureus DNA gyrase ATPase inhibition study, which revealed that compounds 8b , 9c , and 9d showed the highest inhibitory activity with IC₅₀ values of 1.89, 2.73, and 2.14 μM, respectively, comparable to novobiocin (IC₅₀, 1.636 μM). Compounds 2a–c , 3a , 7c , 9c,d , and 10a,b revealed half the potency of levofloxacin in inhibiting the growth of Pseudomonas aeruginosa. As an attempt to rationalize the observed antibacterial activity for the most active compounds 8b , 9c , and 9d , molecular docking in the ATP binding site of S. aureus gyrase B was performed using Glide. Such compounds could be considered as promising scaffolds for the development of new potent antibacterial agents.     

Synthesis and antimicrobial activity of substituted amides and hydrazides of N-acyl-5-bromanthranilic acids

A series of 17 new substituted amides and hydrazides of N-acyl-5-bromanthranilic acids were synthesized. The antimicrobial activity of these compounds with respect to St. aureus and E. coli was evaluated. It was found that of N-chloracetyl-5-bromanthranlic acid methylamide and hydrazide significantly suppressed the growth of test microbes, with a minimum inhibitory concentration of 15.6 mg/ml against St. aureus and 15.6–31.5 mg/ml against E. coli. The other tested compounds were significantly less active. __________ Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 41, No. 9, pp. 29–31, September, 2007.     

Synthesis and antimicrobial activity of new 2‐piperazin‐1‐yl‐N‐1,3‐thiazol‐2‐ylacetamides of cyclopenta[c]pyridines and pyrano[3,4‐c]pyridines

In this study, we report the synthesis and antimicrobial activity of some new disubstituted piperazines. Thus, 3‐chlorocyclopenta[c]pyridines and 6‐chloropyrano[3,4‐c]pyridine 1 under mild reaction conditions with piperazine gave the 3(6)‐piperazine‐substituted cyclopenta[c]pyridines and pyrano[3,4‐c]pyridine 2 . Furthermore, the latter, by alkylation with 2‐chloro‐N‐1,3‐thiazol‐2‐ylacetamide, led to the formation of the target compounds. The evaluation of the antibacterial activity revealed that 3k was the most potent compound. The most sensitive bacterium was found to be Listeria monocytogenes, whereas Staphylococcus aureus was the most resistant one. Three compounds, 3d , 3g , and 3k , were tested also against the following resistant strains: methicillin‐resistant S. aureus (MRSA), Escherichia coli, and Pseudomonas aeruginosa. All three compounds appeared to be more potent than ampicillin against MRSA. Moreover, compound 3d showed a better activity than the reference drug ampicillin against P. aeruginosa, whereas 3g was more efficient against E. coli. The best antifungal activity was observed again for compound 3k . The most resistant fungi appeared to be Aspergillus fumigatus, whereas Trichoderma viride seemed the most sensitive one toward the compounds tested. Molecular docking studies on E. coli MurB, as well as on Candida albicans CYP51 and dihydrofolate reductase, were used for the prediction of the mechanisms of the antibacterial and antifungal activities, confirming the experimental results.     

Antibacterial activity and interactions of plant essential oil combinations against Gram-positive and Gram-negative bacteria

The aim of this study was to compare the antibacterial effects of several essential oils (EOs) alone and in combination against different Gram-positive and Gram-negative bacteria associated with food products. Parsley, lovage, basil, and thyme EOs, as well as their mixtures (1:1, v/v), were tested against Bacillus cereus, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Salmonella typhimurium. The inhibitory effects ranged from strong (thyme EO against E. coli) to no inhibition (parsley EO against P. aeruginosa). Thyme EO exhibited strong (against E. coli), moderate (against S. typhimurium and B. cereus), or mild inhibitory effects (against P. aeruginosa and S. aureus), and basil EO showed mild (against E. coli and B. cereus) or no inhibitory effects (against S. typhimurium, P. aeruginosa, and S. aureus). Parsley and lovage EOs revealed no inhibitory effects against all tested strains. Combinations of lovage/thyme and basil/thyme EOs displayed antagonistic effects against all bacteria, parsley/thyme EOs against B. cereus, S. aureus, P. aeruginosa, and E. coli, and lovage/basil EOs against B. cereus and E. coli. Combinations of parsley/lovage and parsley/basil EOs exhibited indifferent effects against all bacteria. The combination of lovage/basil EO showed indifferent effect against S. aureus, P. aeruginosa, and S. typhimurium, and the combination parsley/thyme EO against S. typhimurium. Thyme EO has the highest percentage yield and antibacterial potential from all tested formulations; its combination with parsley, lovage, and basil EOs determines a reduction of its antibacterial activity. Hence, it is recommended to be used alone as the antibacterial agent.     

New fluoroquinolone compounds with endo‐nortropine derivatives at C‐7 position show antibacterial activity against fluoroquinolone‐resistant strains of Staphylococcus aureus

A series of new fluoroquinolone analogs ( 3 – 18) were prepared, in three steps, by substituting chloro esters and esters with cyclic amines on the C‐7 endo‐nortropine derivatives of difluoroquinolone acid. All the synthesized compounds displayed good MIC against the Staphylococcus aureus when initially screened for Escherichia coli, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The molecules were further evaluated for their antibacterial activity against fluoroquinolone‐resistant strains of S. aureus and for cytotoxic assay. Based on the results, five of the sixteen compounds displayed the potential to be developed further for treatment against fluoroquinolone‐resistant strains of S. aureus.     

Investigation of Synergism between Combinations of Ciprofloxacin,Polymyxin, Sulphadiazine and p-Aminobenzoic acid

Abstract— Subinhibitory concentrations of combinations of any two of ciprofloxacin, colistin (or polymyxin B), sodium sulphadiazine and p-aminobenzoic acid were shown by checkerboard minimum inhibitory concentration determinations to have synergistic inhibitory activity against Pseudomonas aeruginosa and to have either synergistic or additive activity against Staphylococcus aureus. In addition, sulphadiazine plus either ciprofloxacin or polymyxin showed markedly enhanced killing activity against both P. aeruginosa and S. aureus. p-Aminobenzoic acid plus either ciprofloxacin or polymyxin also demonstrated enhanced killing activity against P. aeruginosa but these combinations were less effective in enhancing activity against S. aureus. Ciprofloxacin in combination with polymyxin had a marked synergistic effect against P. aeruginosa but only a slight synergistic effect against S. aureus. These findings indicate a potential usefulness for the synergistic combinations against P. aeruginosa and S. aureus in the clinical situation; that is, they indicate an extended role for sulphonamides and support a potential role for p-aminobenzoic acid as enhancers of the activity of primary antibacterial agents such as ciprofloxacin and polymyxin. We suggest that for a second antibacterial to enhance the activity of ciprofloxacin, it may be necessary for the second antibacterial to increase cell permeability so increasing bacterial uptake of ciprofloxacin.     

Post-antibacterial effect of thymol

The antibacterial activity of thymol has been well established and reported in the scientific literature. Continued suppression of bacterial growth following limited exposure to antimicrobial compounds at different concentrations greater than or equal to the minimum inhibitory concentration level (MIC) and at concentrations less than the MIC can be used as an indicator of biological activity, and are respectively referred to as a post-antibacterial effect (PAE) and a post-antibiotic sub-MIC effect (PA-SME). In this study, the PAE and the PA-SME of thymol against Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Bacillus cereus were investigated. A spectrophotometric method was used to determine the PAE and the PA-SME of thymol against the selected test strains. Thymol exhibited a considerable PAE and PA-SME at MIC and sub-MIC concentrations against test strains. The greatest duration of both the PAE and the PA-SME was observed for thymol against E. coli and P. aeruginosa. The PAE and PA-SME times for E. coli were 12 and 8?h, respectively, and for P. aeruginosa were 11 and 7.5?h, respectively. The duration of the PAE and PA-SME observed for S. aureus and B. cereus was shorter than for Gram-negative strains.     

Synthesis and antimicrobial activities of N-chloroacetyl-2,6-diarylpiperidin-4-ones

An array of new N-chloroacetyl-2,6-diarylpiperidin-4-ones has been synthesised and their antibacterial activity against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, Pseudomonas aeruginosa, and Salmonella typhi, and antifungal activity against Cryptococcus neoformans, Candida albicans, Rhizopus sp., Aspergillus flavus, and Aspergillus niger examined. Compounds 14 against P. aeruginosa, 15 against S. typhi, 16 against S. aureus, and 19 against B. subtilis showed marked antibacterial activity. Similarly, compounds 15 and 19 against A. niger and 19 against A. flavus exerted significant antifungal activities.     

Catechol-bearing imidazolium and benzimidazolium chlorides as promising antimicrobial agents

Catechol-containing imidazolium (four) and benzimidazolium chlorides (eight) were synthesized to evaluate their antimicrobial properties. All the compounds were fully characterized using ¹H and ¹³C nuclear magnetic resonance, liquid chromatography–mass spectrometry, infrared spectroscopic methods, and elemental analyses. Antimicrobial activities of the compounds were tested against the bacteria Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), Enterococcus faecalis, and the fungal strains Candida albicans and Candida glabrata, and promising results were achieved. The two most important benzyl-substituted benzimidazolium chlorides, 3l and 3k , showed comparable activity to vancomycin against MRSA.     

In vitro andin vivo evaluations of LB10517, a novel parenteral broad-spectrum cephalosporin

Thein vitro activity of LB10517, a new catechol-substituted cephalosporin, was compared with those of E-1077, cefpirome and ceftazidime against 1034 clinical isolates collected in Japan. LB10517 showed a broad-spectrum antibacterial activity against a wide range of gram-positive and gram-negative bacteria including non-glucose fermenting rods,Pseudomonas aeruginosa. Against the methicillin-susceptible strains ofStaphylococcus aureus (MSSA) andStreptococcus pyogenes, the MIC₉₀ values of LB10517 which required to inhibit 90% of the strains were 3.13 μg/ml and 0.1 μ/ml, respectively. It was as active as E-1077 but more active than cefpirome and ceftazidime. Methicillin-resistant strains ofS. aureus (MRSA) andEnterococcus spp. were highly resistant to all the test compounds. LB10517 was highly active against most members of the familyEnterobacteriaceae, 90% of which were inhibited at a concentration of less than 0.78 μg/ml, except forEnterobacter cloacae (1.56 μg/ml) andSerratia marcescens (3.13 μg/ml). Its activity was comparable to those of E-1077 and cefpirome but it was greater than that of ceftazidime. AgainstPseudomonas aeruginosa, LB10517 showed the most potent antibacterial activity among the compounds tested. Ninety percent ofP. aeruginosa isolates were susceptible at the concentration of 0.39 μg/ml. Its activity was 32- to 128-fold higher than those of E-1077, cefpirome and ceftazidime. Against imipenem- or ofloxacinresistantP. aeruginosa, LB10517 with MIC₉₀s of 6.25 μg/ml and 3.13 μg/ml, respectively, showed 16-fold more potent activity than the other test compounds. LB10517 showed a relatively high plasma level and long plasma elimination half-life in rats (t_1/2(β), 52 min) and dogs (t_1/2(β), 103 min).     

7-(3-氨基-4-烷氧亚胺基-1-哌啶基)喹诺酮类化合物的合成与抗菌作用

为寻找新的更加优秀的喹诺酮类抗菌药，设计合成了21个7-(3-氨基-4-烷氧亚胺基-1-哌啶基)喹诺酮类化合物，并测定其体内外抗菌活性。化合物结构经¹H NMR和HRMS得到确证，并用单晶X-衍射分析确定其双键构型。化合物14a和14m表现出优秀的广谱抗菌活性，它们对所实验的12株革兰氏阳性菌的活性，总体上明显优于3个对照药，特别是对包括MRSA和MRSE在内的金葡菌和表葡菌的活性是吉米沙星和巴罗沙星的4～16倍、左氧氟沙星的8～64倍。它们对金葡菌的MIC值分别是0.25～1 mg·L^-1和0.125～1 mg·L^-1，对表葡菌的MIC值分别是0.5～4 mg·L^-1和1～8 mg·L^-1，对小鼠系统感染的体内保护作用与吉米沙星、莫西沙星基本相当(P>0.05)。     

Preliminary studies on the antibacterial activity of crude extracts and alkaloids from species of Aspidosperma

Screening tests of hydroethanolic crude extracts of six species of Aspidosperma (Apocynaceae) against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa were performed. Aspidosperma ramiflorum Muell. Arg. showed good activity against Bacillus subtilis with MIC and MBC of 15.7 and 125?μg/mL, moderate activity against Staphylococcus aureus with MIC and MBC of 250 and 500?μg/mL, and weak activity against Escherichia coli with MIC and MBC of 1000?μg/mL. Aspidosperma pyricolum Muell. Arg. (MIC/MBC 125/250?μg/mL) and Aspidosperma olivaceum Muell. Arg. (MIC/MBC 250/?>?1000?μg/mL) displayed moderate antibacterial activity against Bacillus subtilis. Separation of the crude extract of Aspidosperma ramiflorum was performed according to the usual acid–base process, which produces alkaloid mixtures and closely related metabolites. The basic fraction was active against Bacillus subtilis, Staphylococcus aureus, and Escherichia coli, with MICs of 31.2, 62.5, and 250?μg/mL, respectively. The basic fractions were more active than the acid fractions, probably because they contained some active alkaloids and/or closely related metabolites absent from the other fractions, or they contained a higher concentration of these active compounds.     

Synthesis,crystal structure,and ADME prediction studies of novel imidazopyrimidines as antibacterial and cytotoxic agents

In the present study, a novel series of polyfunctionalized imidazopyrimidines 6a–u and 9a–d were efficiently constructed by a domino reaction between 2-imino-6-substituted-2,3-dihydropyrimidin-4(1H)-ones 4a–d or 8a–c and 2-bromoacetophenones 5a–i under mild basic conditions. The synthesized series were screened for their antibacterial activity against Staphylococcus aureus and Bacillus subtilis as Gram-positive (+) bacteria, as well as against Gram-negative (−) bacteria Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Salmonella typhi. Most of the synthesized derivatives of imidazopyrimidines 6 and 9 showed remarkable selectivity against Gram(−) bacteria over the Gram(+) ones. Compounds 6c , 6f , and 6g displayed potent and broad-spectrum antibacterial activity against all tested strains. Compounds 6f and 6g displayed promising inhibitory activity on GryB ATPase from E. coli with IC₅₀ = 1.14 and 0.73 μM, respectively. Simultaneously, some of the synthesized imidazopyrimidines were screened for their antiproliferative activity against 60 cancer cell lines at a concentration of 10 μM. Compound 9d showed potent activity against most of the tested cell lines, with a mean growth inhibition of 37%. The ADME (absorption, distribution, metabolism, and excretion) prediction study demonstrated that the synthesized hits have, in addition to their promising chemotherapeutic activity, acceptable pharmacokinetic properties, and a drug-likeness nature to be further developed.     

Potent antibacterial activity of dihydydropyrimidine‐1,3,5‐triazines via inhibition of DNA gyrase and antifungal activity with favourable metabolic profile

The compounds were tested against panel of three Gram‐positive, viz. Staphylococcus aureus, Bacillus subtilis, Bacillus cereus and three Gram‐negative bacterial strains viz. Pseudomonas aeruginosa, Escherichia coli, and Proteus vulgaris where they showed significant to moderate antibacterial activity. The compound also showed considerable antibiofilm activity against S. aureus and B. subtilis. The most potent compounds 7l and 7m found bacteriostatic in time‐kill assay via inhibition of DNA gyrase enzyme and interacting with Glu58, Val130, Ile175 and Ile186 via numerous H‐bonds as revealed by docking. In S. aureus‐induced murine infection model, compound 7m showed dose‐dependent reduction of viability of bacteria with maximum activity in 25 mg/kg treated group. The antifungal activity against human fungal pathogens was also estimated, where these compounds showed considerable inhibitory activity as compared to standard. The metabolic liability of compound 7m was determined using RS‐Predictor and MetaPrint 2D React. The molecules were proved as effective antibacterial agent via inhibition of DNA gyrase as a mechanism together with significant antifungal activity.     

Cytotoxicity,antiviral and antimicrobial activities of alkaloids,flavonoids, and phenolic acids

Objective: Some natural products consisting of the alkaloids yohimbine and vincamine (indole-type), scopolamine and atropine (tropane-type), colchicine (tropolone-type), allantoin (imidazolidine-type), trigonelline (pyridine-type) as well as octopamine, synephrine, and capsaicin (exocyclic amine-type); the flavonoid derivatives quercetin, apigenin, genistein, naringin, silymarin, and silibinin; and the phenolic acids namely gallic acid, caffeic acid, chlorogenic acid, and quinic acid, were tested for their in vitro antiviral, antibacterial, and antifungal activities and cytotoxicity.

Materials and methods: Antiviral activity of the compounds was tested against DNA virus herpes simplex type 1 and RNA virus parainfluenza (type-3). Cytotoxicity of the compounds was determined using Madin-Darby bovine kidney and Vero cell lines, and their cytopathogenic effects were expressed as maximum non-toxic concentration. Antibacterial activity was assayed against following bacteria and their isolated strains: Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecalis, and Bacillus subtilis, although they were screened by microdilution method against two fungi: Candida albicans and Candida parapsilosis.

Results: Atropine and gallic acid showed potent antiviral effect at the therapeutic range of 0.8–0.05 µg ml^?1, whilst all of the compounds exerted robust antibacterial effect.

Conclusion: Antiviral and antimicrobial effects of the compounds tested herein may constitute a preliminary step for further relevant studies to identify the mechanism of action.